TORONTO--(BUSINESS WIRE)-- Vasomune Therapeutics, Inc. ("Vasomune"), a clinical-stage biopharmaceutical company developing therapies that target endotheliopathy to prevent and reverse vascular leak, today announced that it is receiving advisory services and research and development funding of up to $280,347, through the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

Endotheliopathy, or the breakdown of the endothelial barrier that lines blood vessels, allows fluid and proteins to quickly escape circulation and leak into surrounding tissues, often causing edema and organ failure. The resulting vascular leak is a common and deadly underlying pathology seen in conditions of concern to defence and public health authorities such as acute respiratory distress syndrome (ARDS), hemorrhagic shock, trauma and shock following severe burns.

Vasomune Therapeutics Receives Funding Assistance to Advance Its Dual-Use Vascular Leak Therapy

Business Wire